These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Hurren KM; Berlie HD Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982 [TBL] [Abstract][Full Text] [Related]
3. Directly Observable Behavioral Effects of Lorcaserin in Rats. Serafine KM; Rice KC; France CP J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326 [TBL] [Abstract][Full Text] [Related]
4. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel? Miller KJ; Wacker DA Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799 [TBL] [Abstract][Full Text] [Related]
5. Role of impulsivity and reward in the anti-obesity actions of 5-HT Higgins GA; Zeeb FD; Fletcher PJ J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522 [TBL] [Abstract][Full Text] [Related]
6. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Nigro SC; Luon D; Baker WL Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263 [TBL] [Abstract][Full Text] [Related]
8. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809 [TBL] [Abstract][Full Text] [Related]
9. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Higgins GA; Fletcher PJ; Shanahan WR Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010 [TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of lorcaserin in the management of obesity. Hess R; Cross LB Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762 [TBL] [Abstract][Full Text] [Related]
11. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. Levin ED; Johnson JE; Slade S; Wells C; Cauley M; Petro A; Rose JE J Pharmacol Exp Ther; 2011 Sep; 338(3):890-6. PubMed ID: 21636655 [TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability review of lorcaserin in clinical trials. Greenway FL; Shanahan W; Fain R; Ma T; Rubino D Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785 [TBL] [Abstract][Full Text] [Related]
13. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. Nguyen CT; Zhou S; Shanahan W; Fain R Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281 [TBL] [Abstract][Full Text] [Related]